Abstract

Acute graft-versus-host disease (GVHD) is 1 of the major life-threating complications after allogeneic cell transplantation. Although steroids remain first-line treatment, roughly one-half of patients will develop steroid-refractory GVHD (SR-GVHD), which portends an extremely poor prognosis. Many agents that have shown encouraging response rates in early phase 1/2 trials for prevention and treatment have been unsuccessful in demonstrating a survival advantage when applied in the setting of SR-GVHD. The discovery of novel treatments has been further complicated by the absence of clinically informative animal models that address what may reflect a distinct pathophysiology. Nonetheless, the combined knowledge of established bone marrow transplantation models and recent human trials in SR-GVHD patients are beginning to illuminate novel mechanisms for inhibiting T-cell signaling and promoting tissue tolerance that provide an increased understanding of the underlying biology of SR-GVHD. Here, we discuss recent findings of newly appreciated cellular and molecular mechanisms and provide novel translational opportunities for advancing the effectiveness of treatment in SR-GVHD.

REFERENCES

1.
Jagasia
M
,
Arora
M
,
Flowers
ME
, et al
.
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
.
Blood
.
2012
;
119
(
1
):
296
-
307
.
2.
MacMillan
ML
,
Weisdorf
DJ
,
Wagner
JE
, et al
.
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems
.
Biol Blood Marrow Transplant
.
2002
;
8
(
7
):
387
-
394
.
3.
Levine
JE
,
Braun
TM
,
Harris
AC
, et al;
Blood and Marrow Transplant Clinical Trials Network
.
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
.
Lancet Haematol
.
2015
;
2
(
1
):
e21
-
e29
.
4.
Martin
PJ
,
Rizzo
JD
,
Wingard
JR
, et al
.
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
.
Biol Blood Marrow Transplant
.
2012
;
18
(
8
):
1150
-
1163
.
5.
Xhaard
A
,
Rocha
V
,
Bueno
B
, et al
.
Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment
.
Biol Blood Marrow Transplant
.
2012
;
18
(
3
):
406
-
413
.
6.
Deeg
HJ
.
How I treat refractory acute GVHD
.
Blood
.
2007
;
109
(
10
):
4119
-
4126
.
7.
Socié
G
,
Vigouroux
S
,
Yakoub-Agha
I
, et al
.
A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD
.
Blood
.
2017
;
129
(
5
):
643
-
649
.
8.
Ferrara
JL
,
Levine
JE
,
Reddy
P
,
Holler
E
.
Graft-versus-host disease
.
Lancet
.
2009
;
373
(
9674
):
1550
-
1561
.
9.
Wilhelm
K
,
Ganesan
J
,
Müller
T
, et al
.
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
.
Nat Med
.
2010
;
16
(
12
):
1434
-
1438
.
10.
Koehn
BH
,
Saha
A
,
McDonald-Hyman
C
, et al
.
Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD
.
Blood
.
2019
;
134
(
19
):
1670
-
1682
.
11.
Cooke
KR
,
Hill
GR
,
Crawford
JM
, et al
.
Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease
.
J Clin Invest
.
1998
;
102
(
10
):
1882
-
1891
.
12.
Teshima
T
,
Ordemann
R
,
Reddy
P
, et al
.
Acute graft-versus-host disease does not require alloantigen expression on host epithelium
.
Nat Med
.
2002
;
8
(
6
):
575
-
581
.
13.
Koyama
M
,
Kuns
RD
,
Olver
SD
, et al
.
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease
.
Nat Med
.
2011
;
18
(
1
):
135
-
142
.
14.
Hashimoto
D
,
Chow
A
,
Noizat
C
, et al
.
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes
.
Immunity
.
2013
;
38
(
4
):
792
-
804
.
15.
Koyama
M
,
Mukhopadhyay
P
,
Schuster
IS
, et al
.
MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota
.
Immunity
.
2019
;
51
(
5
):
885
-
898.e7
.
16.
Taylor
PA
,
Ehrhardt
MJ
,
Lees
CJ
, et al
.
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
.
Blood
.
2008
;
112
(
8
):
3508
-
3516
.
17.
Jankovic
D
,
Ganesan
J
,
Bscheider
M
, et al
.
The Nlrp3 inflammasome regulates acute graft-versus-host disease
.
J Exp Med
.
2013
;
210
(
10
):
1899
-
1910
.
18.
Koyama
M
,
Cheong
M
,
Markey
KA
, et al
.
Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease
.
J Exp Med
.
2015
;
212
(
8
):
1303
-
1321
.
19.
Toubai
T
,
Malter
C
,
Tawara
I
, et al
.
Immunization with host-type CD8alpha+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner
.
Blood
.
2010
;
115
(
3
):
724
-
735
.
20.
Highfill
SL
,
Rodriguez
PC
,
Zhou
Q
, et al
.
Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
.
Blood
.
2010
;
116
(
25
):
5738
-
5747
.
21.
D’Aveni
M
,
Rossignol
J
,
Coman
T
, et al
.
G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease
.
Sci Transl Med
.
2015
;
7
(
281
):
281ra42
.
22.
Hülsdünker
J
,
Thomas
OS
,
Haring
E
, et al
.
Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity
.
Proc Natl Acad Sci USA
.
2019
;
116
(
41
):
20700
-
20706
.
23.
Schwab
L
,
Goroncy
L
,
Palaniyandi
S
, et al
.
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage
.
Nat Med
.
2014
;
20
(
6
):
648
-
654
.
24.
Jenq
RR
,
van den Brink
MRM
.
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
.
Nat Rev Cancer
.
2010
;
10
(
3
):
213
-
221
.
25.
Shono
Y
,
Docampo
MD
,
Peled
JU
, et al
.
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice
.
Sci Transl Med
.
2016
;
8
(
339
):
339ra71
.
26.
Legoff
J
,
Resche-Rigon
M
,
Bouquet
J
, et al
.
The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease
.
Nat Med
.
2017
;
23
(
9
):
1080
-
1085
.
27.
Shono
Y
,
van den Brink
MRM
.
Gut microbiota injury in allogeneic haematopoietic stem cell transplantation
.
Nat Rev Cancer
.
2018
;
18
(
5
):
283
-
295
.
28.
Hanash
AM
,
Dudakov
JA
,
Hua
G
, et al
.
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease
.
Immunity
.
2012
;
37
(
2
):
339
-
350
.
29.
Fu
YY
,
Egorova
A
,
Sobieski
C
, et al
.
T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation
.
Immunity
.
2019
;
51
(
1
):
90
-
103.e3
.
30.
Zhao
D
,
Kim
YH
,
Jeong
S
, et al
.
Survival signal REG3α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease
.
J Clin Invest
.
2018
;
128
(
11
):
4970
-
4979
.
31.
Mathewson
ND
,
Jenq
R
,
Mathew
AV
, et al
.
Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease [published correction appears in Nat Immunol. 2016;17(10):1235]
.
Nat Immunol
.
2016
;
17
(
5
):
505
-
513
.
32.
Fujiwara
H
,
Docampo
MD
,
Riwes
M
, et al
.
Microbial metabolite sensor GPR43 controls severity of experimental GVHD
.
Nat Commun
.
2018
;
9
(
1
):
3674
.
33.
Swimm
A
,
Giver
CR
,
DeFilipp
Z
, et al
.
Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
.
Blood
.
2018
;
132
(
23
):
2506
-
2519
.
34.
Toubai
T
,
Rossi
C
,
Oravecz-Wilson
K
, et al
.
IAPs protect host target tissues from graft-versus-host disease in mice
.
Blood Adv
.
2017
;
1
(
19
):
1517
-
1532
.
35.
Toubai
T
,
Fujiwara
H
,
Rossi
C
, et al
.
Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition
.
Nat Microbiol
.
2019
;
4
(
5
):
800
-
812
.
36.
Fischer
JC
,
Bscheider
M
,
Eisenkolb
G
, et al
.
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury
.
Sci Transl Med
.
2017
;
9
(
386
):
eaag2513
.
37.
Fischer
JC
,
Bscheider
M
,
Eisenkolb
G
, et al
.
RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury
.
Sci Transl Med
.
2017
;
9
(
386
):
eaag2513
.
38.
Zeiser
R
,
Blazar
BR
.
Acute graft-versus-host disease - biologic process, prevention, and therapy
.
N Engl J Med
.
2017
;
377
(
22
):
2167
-
2179
.
39.
Hippen
KL
,
Aguilar
EG
,
Rhee
SY
,
Bolivar-Wagers
S
,
Blazar
BR
.
Distinct regulatory and effector T cell metabolic demands during graft-versus-host disease
.
Trends Immunol
.
2020
;
41
(
1
):
77
-
91
.
40.
Wu
SR
,
Reddy
P
.
Tissue tolerance: a distinct concept to control acute GVHD severity
.
Blood
.
2017
;
129
(
13
):
1747
-
1752
.
41.
Edinger
M
,
Hoffmann
P
,
Ermann
J
, et al
.
CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
.
Nat Med
.
2003
;
9
(
9
):
1144
-
1150
.
42.
Taylor
PA
,
Lees
CJ
,
Blazar
BR
.
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality
.
Blood
.
2002
;
99
(
10
):
3493
-
3499
.
43.
Barnes
PJ
,
Adcock
IM
.
Glucocorticoid resistance in inflammatory diseases
.
Lancet
.
2009
;
373
(
9678
):
1905
-
1917
.
44.
Cain
DW
,
Cidlowski
JA
.
Immune regulation by glucocorticoids
.
Nat Rev Immunol
.
2017
;
17
(
4
):
233
-
247
.
45.
Vandewalle
J
,
Luypaert
A
,
De Bosscher
K
,
Libert
C
.
Therapeutic mechanisms of glucocorticoids
.
Trends Endocrinol Metab
.
2018
;
29
(
1
):
42
-
54
.
46.
Groeneweg
FL
,
Karst
H
,
de Kloet
ER
,
Joëls
M
.
Rapid non-genomic effects of corticosteroids and their role in the central stress response
.
J Endocrinol
.
2011
;
209
(
2
):
153
-
167
.
47.
Vodanovic-Jankovic
S
,
Hari
P
,
Jacobs
P
,
Komorowski
R
,
Drobyski
WR
.
NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145
.
Blood
.
2006
;
107
(
2
):
827
-
834
.
48.
MacDonald
KP
,
Kuns
RD
,
Rowe
V
, et al
.
Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD
.
Blood
.
2007
;
109
(
11
):
5049
-
5057
.
49.
Ogawa
S
,
Lozach
J
,
Benner
C
, et al
.
Molecular determinants of crosstalk between nuclear receptors and toll-like receptors
.
Cell
.
2005
;
122
(
5
):
707
-
721
.
50.
Guiducci
C
,
Gong
M
,
Xu
Z
, et al
.
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
.
Nature
.
2010
;
465
(
7300
):
937
-
941
.
51.
Kitajima
T
,
Ariizumi
K
,
Bergstresser
PR
,
Takashima
A
.
A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line
.
J Clin Invest
.
1996
;
98
(
1
):
142
-
147
.
52.
Werb
Z
,
Foley
R
,
Munck
A
.
Interaction of glucocorticoids with macrophages. Identification of glucocorticoid receptors in monocytes and macrophages
.
J Exp Med
.
1978
;
147
(
6
):
1684
-
1694
.
53.
Luther
C
,
Adamopoulou
E
,
Stoeckle
C
, et al
.
Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients
.
J Immunol
.
2009
;
183
(
2
):
841
-
848
.
54.
Ehrchen
J
,
Steinmüller
L
,
Barczyk
K
, et al
.
Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes
.
Blood
.
2007
;
109
(
3
):
1265
-
1274
.
55.
Szatmari
I
,
Nagy
L
.
Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function
.
EMBO J
.
2008
;
27
(
18
):
2353
-
2362
.
56.
Vacca
A
,
Felli
MP
,
Farina
AR
, et al
.
Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements
.
J Exp Med
.
1992
;
175
(
3
):
637
-
646
.
57.
Bianchi
M
,
Meng
C
,
Ivashkiv
LB
.
Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids
.
Proc Natl Acad Sci USA
.
2000
;
97
(
17
):
9573
-
9578
.
58.
Löwenberg
M
,
Tuynman
J
,
Bilderbeek
J
, et al
.
Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn
.
Blood
.
2005
;
106
(
5
):
1703
-
1710
.
59.
Kumamaru
E
,
Numakawa
T
,
Adachi
N
,
Kunugi
H
.
Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB
.
FEBS Lett
.
2011
;
585
(
20
):
3224
-
3228
.
60.
Franchimont
D
,
Galon
J
,
Gadina
M
, et al
.
Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes
.
J Immunol
.
2000
;
164
(
4
):
1768
-
1774
.
61.
Liberman
AC
,
Refojo
D
,
Druker
J
, et al
.
The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction
.
FASEB J
.
2007
;
21
(
4
):
1177
-
1188
.
62.
Ramírez
F
,
Fowell
DJ
,
Puklavec
M
,
Simmonds
S
,
Mason
D
.
Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro
.
J Immunol
.
1996
;
156
(
7
):
2406
-
2412
.
63.
Karagiannidis
C
,
Akdis
M
,
Holopainen
P
, et al
.
Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma
.
J Allergy Clin Immunol
.
2004
;
114
(
6
):
1425
-
1433
.
64.
Yosef
N
,
Shalek
AK
,
Gaublomme
JT
, et al
.
Dynamic regulatory network controlling TH17 cell differentiation
.
Nature
.
2013
;
496
(
7446
):
461
-
468
.
65.
Bouazzaoui
A
,
Spacenko
E
,
Mueller
G
, et al
.
Steroid treatment alters adhesion molecule and chemokine expression in experimental acute graft-vs.-host disease of the intestinal tract
.
Exp Hematol
.
2011
;
39
(
2
):
238
-
249.e1
.
66.
Small
GR
,
Hadoke
PW
,
Sharif
I
, et al
.
Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis
.
Proc Natl Acad Sci USA
.
2005
;
102
(
34
):
12165
-
12170
.
67.
Wu
SR
,
Reddy
P
.
Regulating damage from sterile inflammation: a tale of two tolerances
.
Trends Immunol
.
2017
;
38
(
4
):
231
-
235
.
68.
Cidlowski
JA
,
Munck
A
.
Concanavalin A-induced glucocorticoid resistance in rat thymus cells: decreased cytoplasmic and nuclear receptor binding of dexamethasone
.
J Steroid Biochem
.
1976
;
7
(
11-12
):
1141
-
1145
.
69.
Rodriguez
JM
,
Monsalves-Alvarez
M
,
Henriquez
S
,
Llanos
MN
,
Troncoso
R
.
Glucocorticoid resistance in chronic diseases
.
Steroids
.
2016
;
115
:
182
-
192
.
70.
Zeiser
R
,
Nguyen
VH
,
Beilhack
A
, et al
.
Inhibition of CD4+ CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
.
Blood
.
2006
;
108
(
1
):
390
-
399
.
71.
Toubai
T
,
Rossi
C
,
Tawara
I
, et al
.
Murine models of steroid refractory graft-versus-host disease
.
Sci Rep
.
2018
;
8
(
1
):
12475
.
72.
Kappel
LW
,
Goldberg
GL
,
King
CG
, et al
.
IL-17 contributes to CD4-mediated graft-versus-host disease
.
Blood
.
2009
;
113
(
4
):
945
-
952
.
73.
Carlson
MJ
,
West
ML
,
Coghill
JM
,
Panoskaltsis-Mortari
A
,
Blazar
BR
,
Serody
JS
.
In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations
.
Blood
.
2009
;
113
(
6
):
1365
-
1374
.
74.
Banuelos
J
,
Shin
S
,
Cao
Y
, et al
.
BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis
.
Allergy
.
2016
;
71
(
5
):
640
-
650
.
75.
Ramesh
R
,
Kozhaya
L
,
McKevitt
K
, et al
.
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids
.
J Exp Med
.
2014
;
211
(
1
):
89
-
104
.
76.
Muriglan
SJ
,
Ramirez-Montagut
T
,
Alpdogan
O
, et al
.
GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease
.
J Exp Med
.
2004
;
200
(
2
):
149
-
157
.
77.
Li
H
,
Kaiser
TK
,
Borschiwer
M
, et al
.
Glucocorticoid resistance of allogeneic T cells alters the gene expression profile in the inflamed small intestine of mice suffering from acute graft-versus-host disease
.
J Steroid Biochem Mol Biol
.
2019
;
195
:
105485
.
78.
Toubai
T
,
Tawara
I
,
Sun
Y
, et al
.
Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells
.
Blood
.
2012
;
119
(
16
):
3844
-
3853
.
79.
Imamura
M
,
Hashino
S
,
Kobayashi
H
, et al
.
Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease
.
Bone Marrow Transplant
.
1994
;
13
(
6
):
745
-
751
.
80.
Tawara
I
,
Koyama
M
,
Liu
C
, et al
.
Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation
.
Clin Cancer Res
.
2011
;
17
(
1
):
77
-
88
.
81.
Chen
X
,
Das
R
,
Komorowski
R
, et al
.
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease
.
Blood
.
2009
;
114
(
4
):
891
-
900
.
82.
Spoerl
S
,
Mathew
NR
,
Bscheider
M
, et al
.
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
.
Blood
.
2014
;
123
(
24
):
3832
-
3842
.
83.
Carniti
C
,
Gimondi
S
,
Vendramin
A
, et al
.
Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects
.
Clin Cancer Res
.
2015
;
21
(
16
):
3740
-
3749
.
84.
Betts
BC
,
Bastian
D
,
Iamsawat
S
, et al
.
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation
.
Proc Natl Acad Sci USA
.
2018
;
115
(
7
):
1582
-
1587
.
85.
Zeiser
R
,
Burchert
A
,
Lengerke
C
, et al
.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
.
Leukemia
.
2015
;
29
(
10
):
2062
-
2068
.
86.
Molina
ML
,
Guerrero
J
,
Cidlowski
JA
,
Gatica
H
,
Goecke
A
.
LPS regulates the expression of glucocorticoid receptor α and β isoforms and induces a selective glucocorticoid resistance in vitro
.
J Inflamm (Lond)
.
2017
;
14
:
22
.
87.
Dendoncker
K
,
Timmermans
S
,
Vandewalle
J
, et al
.
TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile [published correction appears in Proc Natl Acad Sci USA. 2019;116(31):15745]
.
Proc Natl Acad Sci USA
.
2019
;
116
(
26
):
12942
-
12951
.
88.
Pazdrak
K
,
Straub
C
,
Maroto
R
, et al
.
Cytokine-induced glucocorticoid resistance from eosinophil activation: protein phosphatase 5 modulation of glucocorticoid receptor phosphorylation and signaling
.
J Immunol
.
2016
;
197
(
10
):
3782
-
3791
.
89.
Rider
CF
,
Shah
S
,
Miller-Larsson
A
,
Giembycz
MA
,
Newton
R
.
Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands [published correction appears in PLoS One. 2015;10(5):e0128728]
.
PLoS One
.
2015
;
10
(
1
):
e0116773
.
90.
Paugh
SW
,
Bonten
EJ
,
Savic
D
, et al
.
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells
.
Nat Genet
.
2015
;
47
(
6
):
607
-
614
.
91.
Baake
T
,
Jörß
K
,
Suennemann
J
, et al
.
The glucocorticoid receptor in recipient cells keeps cytokine secretion in acute graft-versus-host disease at bay
.
Oncotarget
.
2018
;
9
(
21
):
15437
-
15450
.
92.
Norden
J
,
Pearce
KF
,
Irving
JAE
, et al
.
The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation
.
Int J Immunogenet
.
2018
;
45
(
5
):
247
-
256
.
93.
Luft
T
,
Conzelmann
M
,
Benner
A
, et al
.
Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease
.
Blood
.
2007
;
110
(
13
):
4535
-
4542
.
94.
Luft
T
,
Dietrich
S
,
Falk
C
, et al
.
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system
.
Blood
.
2011
;
118
(
6
):
1685
-
1692
.
95.
Dietrich
S
,
Falk
CS
,
Benner
A
, et al
.
Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment
.
Biol Blood Marrow Transplant
.
2013
;
19
(
1
):
22
-
27
.
96.
Wall
SA
,
Zhao
Q
,
Yearsley
M
, et al
.
Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD
.
Blood Adv
.
2018
;
2
(
20
):
2619
-
2628
.
97.
Zeisbrich
M
,
Becker
N
,
Benner
A
, et al
.
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD
.
Bone Marrow Transplant
.
2017
;
52
(
10
):
1399
-
1405
.
98.
Jenq
RR
,
Ubeda
C
,
Taur
Y
, et al
.
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation
.
J Exp Med
.
2012
;
209
(
5
):
903
-
911
.
99.
Kakihana
K
,
Fujioka
Y
,
Suda
W
, et al
.
Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
.
Blood
.
2016
;
128
(
16
):
2083
-
2088
.
100.
DeFilipp
Z
,
Peled
JU
,
Li
S
, et al
.
Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity
.
Blood Adv
.
2018
;
2
(
7
):
745
-
753
.
101.
Qi
X
,
Li
X
,
Zhao
Y
, et al
.
Treating steroid refractory intestinal acute graft-vs.-host disease with fecal microbiota transplantation: a pilot study
.
Front Immunol
.
2018
;
9
:
2195
.
102.
Martin
PJ
,
Schoch
G
,
Fisher
L
, et al
.
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment
.
Blood
.
1990
;
76
(
8
):
1464
-
1472
.
103.
MacMillan
ML
,
Weisdorf
DJ
,
Davies
SM
, et al
.
Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2002
;
8
(
1
):
40
-
46
.
104.
Ali
AM
,
DiPersio
JF
,
Schroeder
MA
.
The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review
.
Biol Blood Marrow Transplant
.
2016
;
22
(
9
):
1552
-
1564
.
105.
Paczesny
S
.
Biomarkers for posttransplantation outcomes
.
Blood
.
2018
;
131
(
20
):
2193
-
2204
.
106.
Ho
VT
,
Cutler
C
.
Current and novel therapies in acute GVHD
.
Best Pract Res Clin Haematol
.
2008
;
21
(
2
):
223
-
237
.
107.
MacMillan
ML
,
Robin
M
,
Harris
AC
, et al
.
A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality
.
Biol Blood Marrow Transplant
.
2015
;
21
(
4
):
761
-
767
.
108.
Melson
J
,
Jakate
S
,
Fung
H
,
Arai
S
,
Keshavarzian
A
.
Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease
.
Am J Hematol
.
2007
;
82
(
10
):
881
-
886
.
109.
Levine
JE
,
Huber
E
,
Hammer
ST
, et al
.
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality
.
Blood
.
2013
;
122
(
8
):
1505
-
1509
.
110.
Major-Monfried
H
,
Renteria
AS
,
Pawarode
A
, et al
.
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
.
Blood
.
2018
;
131
(
25
):
2846
-
2855
.
111.
Ferrara
JLM
,
Chaudhry
MS
.
GVHD: biology matters
.
Blood Adv
.
2018
;
2
(
22
):
3411
-
3417
.
112.
Ponce
DM
,
Hilden
P
,
Mumaw
C
, et al
.
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation
.
Blood
.
2015
;
125
(
1
):
199
-
205
.
113.
Vander Lugt
MT
,
Braun
TM
,
Hanash
S
, et al
.
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death
.
N Engl J Med
.
2013
;
369
(
6
):
529
-
539
.
114.
Zhang
J
,
Ramadan
AM
,
Griesenauer
B
, et al
.
ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease
.
Sci Transl Med
.
2015
;
7
(
308
):
308ra160
.
115.
Azramezani Kopi
T
,
Shahrokh
S
,
Mirzaei
S
,
Asadzadeh Aghdaei
H
,
Amini Kadijani
A
.
The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study
.
Gastroenterol Hepatol Bed Bench
.
2019
;
12
(
3
):
183
-
189
.
116.
O’Meara
A
,
Kapel
N
,
Xhaard
A
, et al
.
Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD
.
Bone Marrow Transplant
.
2015
;
50
(
8
):
1105
-
1109
.
117.
Adam
B
,
Koldehoff
M
,
Ditschkowski
M
, et al
.
Endoscopic and histological findings are predicted by fecal calprotectin in acute intestinal graft-versus-host-disease
.
Dig Dis Sci
.
2016
;
61
(
7
):
2019
-
2026
.
118.
Rodriguez-Otero
P
,
Porcher
R
,
Peffault de Latour
R
, et al
.
Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease
.
Blood
.
2012
;
119
(
24
):
5909
-
5917
.
119.
Martin
PJ
,
Inamoto
Y
,
Flowers
ME
,
Carpenter
PA
.
Secondary treatment of acute graft-versus-host disease: a critical review
.
Biol Blood Marrow Transplant
.
2012
;
18
(
7
):
982
-
988
.
120.
Macmillan
ML
,
Couriel
D
,
Weisdorf
DJ
, et al
.
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
.
Blood
.
2007
;
109
(
6
):
2657
-
2662
.
121.
Martin
PJ
,
Bachier
CR
,
Klingemann
HG
, et al
.
Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement
.
Biol Blood Marrow Transplant
.
2009
;
15
(
7
):
777
-
784
.
122.
MacMillan
ML
,
DeFor
TE
,
Weisdorf
DJ
.
The best endpoint for acute GVHD treatment trials
.
Blood
.
2010
;
115
(
26
):
5412
-
5417
.
123.
Martin
PJ
.
Study design and endpoints in graft-versus-host disease
.
Best Pract Res Clin Haematol
.
2008
;
21
(
2
):
357
-
372
.
124.
Van Lint
MT
,
Uderzo
C
,
Locasciulli
A
, et al
.
Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation
.
Blood
.
1998
;
92
(
7
):
2288
-
2293
.
125.
Meyer
EH
,
Hsu
AR
,
Liliental
J
, et al
.
A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease
.
Blood
.
2013
;
121
(
24
):
4955
-
4962
.
126.
Bolaños-Meade
J
,
Jacobsohn
DA
,
Margolis
J
, et al
.
Pentostatin in steroid-refractory acute graft-versus-host disease
.
J Clin Oncol
.
2005
;
23
(
12
):
2661
-
2668
.
127.
Mayer
J
,
Krejcí
M
,
Doubek
M
, et al
.
Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease
.
Bone Marrow Transplant
.
2005
;
35
(
7
):
699
-
705
.
128.
Weisdorf
D
,
Haake
R
,
Blazar
B
, et al
.
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome
.
Blood
.
1990
;
75
(
4
):
1024
-
1030
.
129.
Arai
S
,
Margolis
J
,
Zahurak
M
,
Anders
V
,
Vogelsang
GB
.
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
.
Biol Blood Marrow Transplant
.
2002
;
8
(
3
):
155
-
160
.
130.
Holler
E
,
Butzhammer
P
,
Schmid
K
, et al
.
Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2014
;
20
(
5
):
640
-
645
.
131.
Vydra
J
,
Shanley
RM
,
George
I
, et al
.
Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation
.
Clin Infect Dis
.
2012
;
55
(
6
):
764
-
770
.
132.
Perales
MA
,
Ishill
N
,
Lomazow
WA
, et al
.
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease
.
Bone Marrow Transplant
.
2007
;
40
(
5
):
481
-
486
.
133.
García-Cadenas
I
,
Rivera
I
,
Martino
R
, et al
.
Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease
.
Bone Marrow Transplant
.
2017
;
52
(
1
):
107
-
113
.
134.
Schneiderman
J
.
Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease
.
Hematology Am Soc Hematol Educ Program
.
2017
;
2017
:
639
-
644
.
135.
Abu-Dalle
I
,
Reljic
T
,
Nishihori
T
, et al
.
Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies
.
Biol Blood Marrow Transplant
.
2014
;
20
(
11
):
1677
-
1686
.
136.
Groth
C
,
van Groningen
LFJ
,
Matos
TR
, et al
.
Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2019
;
25
(
4
):
712
-
719
.
137.
Carpenter
PA
,
Appelbaum
FR
,
Corey
L
, et al
.
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
.
Blood
.
2002
;
99
(
8
):
2712
-
2719
.
138.
van Oosterhout
YV
,
van Emst
L
,
Schattenberg
AV
, et al
.
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease
.
Blood
.
2000
;
95
(
12
):
3693
-
3701
.
139.
Chen
YB
,
McDonough
S
,
Hasserjian
R
, et al
.
Expression of CD30 in patients with acute graft-versus-host disease
.
Blood
.
2012
;
120
(
3
):
691
-
696
.
140.
Chen
YB
,
Perales
MA
,
Li
S
, et al
.
Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease
.
Blood
.
2017
;
129
(
24
):
3256
-
3261
.
141.
Kekre
N
,
Kim
HT
,
Ho
VT
, et al
.
Phase II trial of natalizumab (Tysabri (R)) with corticosteroids as initial treatment of gastrointestinal acute graft versus host disease [abstract]
.
Biol Blood Marrow Transplant
.
2018
;
24
(
suppl 3
):
S69
.
142.
Fløisand
Y
,
Lundin
KEA
,
Lazarevic
V
, et al
.
Targeting integrin α4β7 in steroid-refractory intestinal graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2017
;
23
(
1
):
172
-
175
.
143.
Fløisand
Y
,
Lazarevic
VL
,
Maertens
J
, et al
.
Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review
.
Biol Blood Marrow Transplant
.
2019
;
25
(
4
):
720
-
727
.
144.
Teshima
T
,
Reddy
P
,
Zeiser
R
.
Reprint of: acute graft-versus-host disease: novel biological insights
.
Biol Blood Marrow Transplant
.
2016
;
22
(
suppl 3
):
S3
-
S8
.
145.
Ganetsky
A
,
Frey
NV
,
Hexner
EO
, et al
.
Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract
.
Bone Marrow Transplant
.
2019
;
54
(
2
):
212
-
217
.
146.
Roddy
JV
,
Haverkos
BM
,
McBride
A
, et al
.
Tocilizumab for steroid refractory acute graft-versus-host disease
.
Leuk Lymphoma
.
2016
;
57
(
1
):
81
-
85
.
147.
Drobyski
WR
,
Pasquini
M
,
Kovatovic
K
, et al
.
Tocilizumab for the treatment of steroid refractory graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2011
;
17
(
12
):
1862
-
1868
.
148.
Betts
BC
,
St Angelo
ET
,
Kennedy
M
,
Young
JW
.
Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses
.
Blood
.
2011
;
118
(
19
):
5340
-
5343
.
149.
Lindemans
CA
,
Calafiore
M
,
Mertelsmann
AM
, et al
.
Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration
.
Nature
.
2015
;
528
(
7583
):
560
-
564
.
150.
van Groningen
LF
,
Liefferink
AM
,
de Haan
AF
, et al
.
Combination therapy with inolimomab and etanercept for severe steroid-refractory acute graft-versus-host disease
.
Biol Blood Marrow Transplant
.
2016
;
22
(
1
):
179
-
182
.
151.
Langlais
D
,
Couture
C
,
Balsalobre
A
,
Drouin
J
.
The Stat3/GR interaction code: predictive value of direct/indirect DNA recruitment for transcription outcome
.
Mol Cell
.
2012
;
47
(
1
):
38
-
49
.
152.
Jagasia
M
,
Perales
MA
,
Schroeder
MA
, et al
.
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
.
Blood
.
2020
;
135
(
20
):
1739
-
1749
.
153.
Abedin
S
,
McKenna
E
,
Chhabra
S
, et al
.
Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation
.
Biol Blood Marrow Transplant
.
2019
;
25
(
8
):
1689
-
1694
.
154.
Schroeder
MA
,
Khoury
HJ
,
Jagasia
M
, et al
.
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
.
Blood Adv
.
2020
;
4
(
8
):
1656
-
1669
.
155.
Mócsai
A
,
Ruland
J
,
Tybulewicz
VL
.
The SYK tyrosine kinase: a crucial player in diverse biological functions
.
Nat Rev Immunol
.
2010
;
10
(
6
):
387
-
402
.
156.
Leonhardt
F
,
Zirlik
K
,
Buchner
M
, et al
.
Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels
.
Leukemia
.
2012
;
26
(
7
):
1617
-
1629
.
157.
Steinbach
G
,
Hockenbery
DM
,
Huls
G
, et al
.
Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease
.
PLoS One
.
2017
;
12
(
8
):
e0183284
.
158.
Krishnamurthy
N
,
Kurzrock
R
.
Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors
.
Cancer Treat Rev
.
2018
;
62
:
50
-
60
.
159.
Tawara
I
,
Sun
Y
,
Lewis
EC
, et al
.
Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation
.
Proc Natl Acad Sci USA
.
2012
;
109
(
2
):
564
-
569
.
160.
Marcondes
AM
,
Karoopongse
E
,
Lesnikova
M
, et al
.
α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics
.
Blood
.
2014
;
124
(
18
):
2881
-
2891
.
161.
Brennan
TV
,
Lin
L
,
Huang
X
, et al
.
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation
.
Blood
.
2012
;
120
(
14
):
2899
-
2908
.
162.
Magenau
JM
,
Goldstein
SC
,
Peltier
D
, et al
.
α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
.
Blood
.
2018
;
131
(
12
):
1372
-
1379
.
163.
Marcondes
AM
,
Hockenbery
D
,
Lesnikova
M
, et al
.
Response of steroid-refractory acute GVHD to α1-antitrypsin
.
Biol Blood Marrow Transplant
.
2016
;
22
(
9
):
1596
-
1601
.
164.
Blazar
BR
,
MacDonald
KPA
,
Hill
GR
.
Immune regulatory cell infusion for graft-versus-host disease prevention and therapy
.
Blood
.
2018
;
131
(
24
):
2651
-
2660
.
165.
Koreth
J
,
Matsuoka
K
,
Kim
HT
, et al
.
Interleukin-2 and regulatory T cells in graft-versus-host disease
.
N Engl J Med
.
2011
;
365
(
22
):
2055
-
2066
.
166.
Kennedy-Nasser
AA
,
Ku
S
,
Castillo-Caro
P
, et al
.
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity
.
Clin Cancer Res
.
2014
;
20
(
8
):
2215
-
2225
.
167.
Mavers
M
,
Maas-Bauer
K
,
Negrin
RS
.
Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation
.
Front Immunol
.
2017
;
8
:
900
.
168.
Wolf
D
,
Barreras
H
,
Bader
CS
, et al
.
Marked in vivo donor regulatory T cell expansion via interleukin-2 and TL1A-Ig stimulation ameliorates graft-versus-host disease but preserves graft-versus-leukemia in recipients after hematopoietic stem cell transplantation
.
Biol Blood Marrow Transplant
.
2017
;
23
(
5
):
757
-
766
.
169.
Hashmi
S
,
Ahmed
M
,
Murad
MH
, et al
.
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis
.
Lancet Haematol
.
2016
;
3
(
1
):
e45
-
e52
.
170.
Galleu
A
,
Riffo-Vasquez
Y
,
Trento
C
, et al
.
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation
.
Sci Transl Med
.
2017
;
9
(
416
):
eaam7828
.
171.
Gooley
TA
,
Chien
JW
,
Pergam
SA
, et al
.
Reduced mortality after allogeneic hematopoietic-cell transplantation
.
N Engl J Med
.
2010
;
363
(
22
):
2091
-
2101
.
172.
Bolaños-Meade
J
,
Reshef
R
,
Fraser
R
, et al
.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
.
Lancet Haematol
.
2019
;
6
(
3
):
e132
-
e143
.
173.
Toubai
T
,
Hou
G
,
Mathewson
N
, et al
.
Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice
.
Blood
.
2014
;
123
(
22
):
3512
-
3523
.
174.
Toubai
T
,
Rossi
C
,
Oravecz-Wilson
K
, et al
.
Siglec-G represses DAMP-mediated effects on T cells
.
JCI Insight
.
2017
;
2
(
14
):
92293
.
175.
Hayase
E
,
Hashimoto
D
,
Nakamura
K
, et al
.
R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease
.
J Exp Med
.
2017
;
214
(
12
):
3507
-
3518
.
176.
Danylesko
I
,
Bukauskas
A
,
Paulson
M
, et al
.
Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease
.
Bone Marrow Transplant
.
2019
;
54
(
7
):
987
-
993
.
177.
Khandelwal
P
,
Teusink-Cross
A
,
Davies
SM
, et al
.
Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients
.
Biol Blood Marrow Transplant
.
2017
;
23
(
7
):
1122
-
1127
.
178.
González Vicent
M
,
Molina
B
,
González de Pablo
J
,
Castillo
A
,
Díaz
MA
.
Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results
.
Am J Hematol
.
2019
;
94
(
3
):
319
-
326
.
You do not currently have access to this content.

Sign in via your Institution

Sign In